Policy | August 27, 2024
India's bioeconomy to reach US $300 billion by 2030: Dr. Jitendra Singh
The new bioeconomy policy rolled out by the Modi government is set to place India as a global leader in the years to come
The new bioeconomy policy rolled out by the Modi government is set to place India as a global leader in the years to come
e brings over 27+ years of rich pharmaceutical experience
MoCRA mandates that all facilities involved in the manufacturing and processing of cosmetic products for sale in the United States
Sun Pharma has obtained rights from MSD to develop, manufacture and commercialise Tedizolid Phosphate in India
Majority of organizations are looking to increase investments in public and hybrid cloud
This accelerates the clinical-to-commercial process timeline and enables customers to develop the right molecule
Against targeted investment of Rs. 3,938 crore, investments worth Rs. 4,024 crores have been made under scheme
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
Sun Pharmaceutical Industries has reported total income of Rs. 13,185.30 crores during the period ended June 30, 2024
Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
